As of 2024-12-15, the Relative Valuation of Akebia Therapeutics Inc (AKBA) is (6.49) USD. This relative valuation is based on P/E multiples. With the latest stock price at 1.85 USD, the upside of Akebia Therapeutics Inc based on Relative Valuation is -451.0%.
The range of the Relative Valuation is (5.81) - (7.29) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 27.6x - 38.5x | 35.9x |
| Forward P/E multiples | 19.0x - 34.6x | 25.7x |
| Fair Price | (5.81) - (7.29) | (6.49) |
| Upside | -414.0% - -493.8% | -451.0% |
| Date | P/E |
| 2024-12-13 | -8.78 |
| 2024-12-12 | -8.63 |
| 2024-12-11 | -9.11 |
| 2024-12-10 | -9.39 |
| 2024-12-09 | -9.68 |
| 2024-12-06 | -9.72 |
| 2024-12-05 | -9.58 |
| 2024-12-04 | -9.63 |
| 2024-12-03 | -9.68 |
| 2024-12-02 | -10.10 |
| 2024-11-29 | -9.77 |
| 2024-11-27 | -9.77 |
| 2024-11-26 | -9.72 |
| 2024-11-25 | -9.16 |
| 2024-11-22 | -8.92 |
| 2024-11-21 | -8.63 |
| 2024-11-20 | -8.49 |
| 2024-11-19 | -8.63 |
| 2024-11-18 | -8.54 |
| 2024-11-15 | -8.49 |
| 2024-11-14 | -8.82 |
| 2024-11-13 | -9.11 |
| 2024-11-12 | -9.25 |
| 2024-11-11 | -9.44 |
| 2024-11-08 | -9.20 |
| 2024-11-07 | -8.85 |
| 2024-11-06 | -9.49 |
| 2024-11-05 | -8.82 |
| 2024-11-04 | -8.78 |
| 2024-11-01 | -8.02 |
| 2024-10-31 | -7.87 |
| 2024-10-30 | -8.06 |
| 2024-10-29 | -8.11 |
| 2024-10-28 | -7.73 |
| 2024-10-25 | -7.54 |
| 2024-10-24 | -7.50 |
| 2024-10-23 | -7.54 |
| 2024-10-22 | -7.78 |
| 2024-10-21 | -6.50 |
| 2024-10-18 | -6.36 |
| 2024-10-17 | -6.31 |
| 2024-10-16 | -6.31 |
| 2024-10-15 | -6.21 |
| 2024-10-14 | -6.26 |
| 2024-10-11 | -6.26 |
| 2024-10-10 | -6.07 |
| 2024-10-09 | -6.07 |
| 2024-10-08 | -6.26 |
| 2024-10-07 | -6.26 |
| 2024-10-04 | -6.31 |